TrialActa dermato-venereologica2021

Secukinumab Exhibits Sustained and Stable Response in Patients with Moderate-to-Severe Psoriasis: Results from the SUPREME Study.

Antonio Costanzo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.